Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

Roy Fleischmann,Jeffrey N Miner,Zancong Shen,Sha Liu,Xiaohong Yan,Jesse Hall,Peter Winkle,Michael Gillen,Martha Hernandez-Illas,Liz Hicks,Shakti Valdez

doi:10.1136/rmdopen-2017-000584

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study

Roy Fleischmann, Jeffrey N Miner + Show 9 more

Open Access

https://doi.org/10.1136/rmdopen-2017-000584

Copy DOI

Journal: RMD Open	Publication Date: Feb 1, 2018
Citations: 32	License type: open-access

Affiliation: The University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Anaheim Clinical Trials, AstraZeneca (United States)

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectivesVerinurad (RDEA3170) is a high affinity, selective uric acid transporter (URAT1) inhibitor indevelopment for treating gout and asymptomatic hyperuricaemia. This phase IIa study evaluated the pharmacodynamics, pharmacokinetics and safety of...

Full Text